{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:17:09Z","timestamp":1787591829116,"version":"build-2736575974"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01 HX002156"],"award-info":[{"award-number":["I01 HX002156"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Implement Sci Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The United States has been grappling with the opioid epidemic, which has resulted in over 75,000 opioid-related deaths between April 2020 and 2021. Evidence-based pharmaceutical interventions (buprenorphine, methadone, and naltrexone) are available to reduce opioid-related overdoses and deaths. However, adoption of these medications for opioid use disorder has been stifled due to individual- and system-level barriers. External facilitation is an evidence-based implementation intervention that has been used to increase access to medication for opioid use disorder (MOUD), but the implementation costs of external facilitation have not been assessed. We sought to measure the facility-level direct costs of implementing an external facilitation intervention for MOUD to provide decision makers with estimates of the resources needed to implement this evidence-based program.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a cost analysis of the pre-implementation and implementation phases, including an itemization of external facilitation team and local site labor costs. We used labor estimates from the Bureau of Labor and Statistics, and sensitivity analyses were performed using labor estimates from the Veterans Health Administration (VHA) Financial Management System general ledger data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The average total costs for implementing an external facilitation intervention for MOUD per site was $18,847 (SD 6717) and ranged between $11,320 and $31,592. This translates to approximately $48 per patient with OUD. Sites with more encounters and participants with higher salaries in attendance had higher costs. This was driven mostly by the labor involved in planning and implementation activities. The average total cost of the pre-implementation and implementation activities were $1031 and $17,816 per site, respectively. In the sensitivity analysis, costs for VHA were higher than BLS estimates likely due to higher wages.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Implementing external facilitation to increase MOUD prescribing may be affordable depending on the payer\u2019s budget constraints. Our study reported that there were variations in the time invested at each phase of implementation and the number and type of participants involved with implementing an external facilitation intervention. Participant composition played an important role in total implementation costs, and decision makers will need to identify the most efficient and optimal number of stakeholders to involve in their implementation plans.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s43058-023-00482-8","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T08:02:14Z","timestamp":1691654534000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Costs of implementing a multi-site facilitation intervention to increase access to medication treatment for opioid use disorder"],"prefix":"10.1186","volume":"4","author":[{"given":"Carla C.","family":"Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7343-9458","authenticated-orcid":false,"given":"Mark","family":"Bounthavong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison M.","family":"Gustavson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie E.","family":"Kenny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aryan","family":"Esmaeili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Princess E.","family":"Ackland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Clothier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Bangerter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siamak","family":"Noorbaloochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex H. S.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildi J.","family":"Hagedorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"issue":"2","key":"482_CR1","first-page":"97","volume":"25","author":"L Manchikanti","year":"2022","unstructured":"Manchikanti L, Singh VM, Staats PS, et al. Fourth wave of opioid (illicit drug) overdose deaths and diminishing access to prescription opioids and interventional techniques: cause and effect. Pain Physician. 2022;25(2):97\u2013124.","journal-title":"Pain Physician"},{"key":"482_CR2","unstructured":"National Institute on Drug Abuse. Overdose death rates: trends and statistics. National Institute on Drug Abuse; 2021. https:\/\/www.drugabuse.gov\/drug-topics\/trends-statistics\/overdose-death-rates. Accessed 8 Feb 2021."},{"key":"482_CR3","unstructured":"CDC\/National Center for Heatlh Statistics. Drug overdose deaths in the U.S. top 100,000 annually. 2021. https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2021\/20211117.htm. Accessed 6 Dec 2021."},{"issue":"12","key":"482_CR4","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s11606-015-3394-3","volume":"30","author":"IA Binswanger","year":"2015","unstructured":"Binswanger IA, Koester S, Mueller SR, Gardner EM, Goddard K, Glanz JM. Overdose education and naloxone for patients prescribed opioids in primary care: a qualitative study of primary care staff. J Gen Intern Med. 2015;30(12):1837\u201344. https:\/\/doi.org\/10.1007\/s11606-015-3394-3.","journal-title":"J Gen Intern Med"},{"issue":"3","key":"482_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/ajad.12364","volume":"25","author":"DC Lott","year":"2016","unstructured":"Lott DC, Rhodes J. Opioid overdose and naloxone education in a substance use disorder treatment program. Am J Addict. 2016;25(3):221\u20136. https:\/\/doi.org\/10.1111\/ajad.12364.","journal-title":"Am J Addict"},{"key":"482_CR6","doi-asserted-by":"publisher","unstructured":"Pauly JB, Vartan CM, Brooks AT. Implementation and evaluation of an opioid overdose education and naloxone distribution (OEND) program at a Veterans Affairs Medical Center. Subst Abuse. 2018:1\u201317. https:\/\/doi.org\/10.1080\/08897077.2018.1449174.","DOI":"10.1080\/08897077.2018.1449174"},{"key":"482_CR7","unstructured":"U.S. Department of Veterans Affairs. Opioid overdose education and naloxone distribution. Office of Research & Development; 2018. https:\/\/www.research.va.gov\/research_in_action\/Opioid-overdose-education-and-naloxone-distribution.cfm. Accessed 12 May 2018."},{"key":"482_CR8","doi-asserted-by":"publisher","first-page":"f174","DOI":"10.1136\/bmj.f174","volume":"346","author":"AY Walley","year":"2013","unstructured":"Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174.","journal-title":"BMJ"},{"issue":"4","key":"482_CR9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.7326\/M15-2771","volume":"165","author":"PO Coffin","year":"2016","unstructured":"Coffin PO, Behar E, Rowe C, et al. Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain. Ann Intern Med. 2016;165(4):245\u201352. https:\/\/doi.org\/10.7326\/M15-2771.","journal-title":"Ann Intern Med"},{"key":"482_CR10","doi-asserted-by":"publisher","unstructured":"National Academies of Sciences, Engineering, and Medicine. Medications for opioid use disorder save lives. The National Academies Press; 2019. https:\/\/doi.org\/10.17226\/25310.","DOI":"10.17226\/25310"},{"issue":"1\u20133","key":"482_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.drugalcdep.2007.11.003","volume":"94","author":"T Clausen","year":"2008","unstructured":"Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend. 2008;94(1\u20133):151\u20137. https:\/\/doi.org\/10.1016\/j.drugalcdep.2007.11.003.","journal-title":"Drug Alcohol Depend"},{"key":"482_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1100\/tsw.2005.52","volume":"5","author":"SM Giacomuzzi","year":"2005","unstructured":"Giacomuzzi SM, Ertl M, Kemmler G, Riemer Y, Vigl A. Sublingual buprenorphine and methadone maintenance treatment: a three-year follow-up of quality of life assessment. ScientificWorldJournal. 2005;5:452\u201368. https:\/\/doi.org\/10.1100\/tsw.2005.52.","journal-title":"ScientificWorldJournal"},{"issue":"5","key":"482_CR13","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1046\/j.1360-0443.2003.00352.x","volume":"98","author":"SM Giacomuzzi","year":"2003","unstructured":"Giacomuzzi SM, Riemer Y, Ertl M, et al. Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health-related quality of life assessment. Addict Abingdon Engl. 2003;98(5):693\u2013702. https:\/\/doi.org\/10.1046\/j.1360-0443.2003.00352.x.","journal-title":"Addict Abingdon Engl"},{"key":"482_CR14","doi-asserted-by":"publisher","unstructured":"Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011;(8):CD004145. https:\/\/doi.org\/10.1002\/14651858.CD004145.pub4.","DOI":"10.1002\/14651858.CD004145.pub4"},{"issue":"3","key":"482_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","volume":"169","author":"MR Larochelle","year":"2018","unstructured":"Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137\u201345. https:\/\/doi.org\/10.7326\/M17-3107.","journal-title":"Ann Intern Med"},{"key":"482_CR16","doi-asserted-by":"publisher","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2):CD002207. https:\/\/doi.org\/10.1002\/14651858.CD002207.pub4.","DOI":"10.1002\/14651858.CD002207.pub4"},{"issue":"5","key":"482_CR17","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1080\/00952990701523698","volume":"33","author":"AM Ponizovsky","year":"2007","unstructured":"Ponizovsky AM, Grinshpoon A. Quality of life among heroin users on buprenorphine versus methadone maintenance. Am J Drug Alcohol Abuse. 2007;33(5):631\u201342. https:\/\/doi.org\/10.1080\/00952990701523698.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"1\u20132","key":"482_CR18","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3109\/10826080902873010","volume":"45","author":"AM Ponizovsky","year":"2010","unstructured":"Ponizovsky AM, Margolis A, Heled L, Rosca P, Radomislensky I, Grinshpoon A. Improved quality of life, clinical, and psychosocial outcomes among heroin-dependent patients on ambulatory buprenorphine maintenance. Subst Use Misuse. 2010;45(1\u20132):288\u2013313. https:\/\/doi.org\/10.3109\/10826080902873010.","journal-title":"Subst Use Misuse"},{"issue":"2","key":"482_CR19","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1176\/appi.ps.201300256","volume":"65","author":"CP Thomas","year":"2014","unstructured":"Thomas CP, Fullerton CA, Kim M, et al. Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatr Serv Wash DC. 2014;65(2):158\u201370. https:\/\/doi.org\/10.1176\/appi.ps.201300256.","journal-title":"Psychiatr Serv Wash DC"},{"issue":"4","key":"482_CR20","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jsat.2013.10.014","volume":"46","author":"J Tkacz","year":"2014","unstructured":"Tkacz J, Volpicelli J, Un H, Ruetsch C. Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients. J Subst Abuse Treat. 2014;46(4):456\u201362. https:\/\/doi.org\/10.1016\/j.jsat.2013.10.014.","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"482_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1056\/NEJMsr1706626","volume":"377","author":"ND Volkow","year":"2017","unstructured":"Volkow ND, Collins FS. The role of science in addressing the opioid crisis. N Engl J Med. 2017;377(4):391\u20134. https:\/\/doi.org\/10.1056\/NEJMsr1706626.","journal-title":"N Engl J Med"},{"issue":"22","key":"482_CR22","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMp1402780","volume":"370","author":"ND Volkow","year":"2014","unstructured":"Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies\u2013tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063\u20136. https:\/\/doi.org\/10.1056\/NEJMp1402780.","journal-title":"N Engl J Med"},{"issue":"8","key":"482_CR23","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1056\/NEJMp2017363","volume":"383","author":"J Berk","year":"2020","unstructured":"Berk J. A good place to start \u2014 low-threshold buprenorphine initiation. N Engl J Med. 2020;383(8):701\u20133. https:\/\/doi.org\/10.1056\/NEJMp2017363.","journal-title":"N Engl J Med"},{"issue":"19","key":"482_CR24","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMp2101298","volume":"384","author":"E Poorman","year":"2021","unstructured":"Poorman E. The number needed to prescribe \u2014 what would it take to expand access to buprenorphine? N Engl J Med. 2021;384(19):1783\u20134. https:\/\/doi.org\/10.1056\/NEJMp2101298.","journal-title":"N Engl J Med"},{"issue":"2","key":"482_CR25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1370\/afm.1595","volume":"12","author":"E Hutchinson","year":"2014","unstructured":"Hutchinson E, Catlin M, Andrilla CHA, Baldwin LM, Rosenblatt RA. Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med. 2014;12(2):128\u201333. https:\/\/doi.org\/10.1370\/afm.1595.","journal-title":"Ann Fam Med"},{"issue":"6 Suppl 3","key":"482_CR26","doi-asserted-by":"publisher","first-page":"S230","DOI":"10.1016\/j.amepre.2017.12.022","volume":"54","author":"RL Haffajee","year":"2018","unstructured":"Haffajee RL, Bohnert ASB, Lagisetty PA. Policy pathways to address provider workforce barriers to buprenorphine treatment. Am J Prev Med. 2018;54(6 Suppl 3):S230\u201342. https:\/\/doi.org\/10.1016\/j.amepre.2017.12.022.","journal-title":"Am J Prev Med"},{"issue":"2","key":"482_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/08897077.2018.1452327","volume":"39","author":"JJ Wyse","year":"2018","unstructured":"Wyse JJ, Gordon AJ, Dobscha SK, et al. Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: historical perspective, lessons learned, and next steps. Subst Abuse. 2018;39(2):139\u201344. https:\/\/doi.org\/10.1080\/08897077.2018.1452327.","journal-title":"Subst Abuse"},{"issue":"1","key":"482_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13722-018-0127-z","volume":"13","author":"H Hagedorn","year":"2018","unstructured":"Hagedorn H, Kenny M, Gordon AJ, et al. Advancing Pharmacological Treatments for Opioid Use Disorder (ADaPT-OUD): protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities. Addict Sci Clin Pract. 2018;13(1):25. https:\/\/doi.org\/10.1186\/s13722-018-0127-z.","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"482_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1748-5908-1-23","volume":"1","author":"CB Stetler","year":"2006","unstructured":"Stetler CB, Legro MW, Rycroft-Malone J, et al. Role of \u201cexternal facilitation\u201d in implementation of research findings: a qualitative evaluation of facilitation experiences in the Veterans Health Administration. Implement Sci. 2006;1(1):23. https:\/\/doi.org\/10.1186\/1748-5908-1-23.","journal-title":"Implement Sci"},{"issue":"4","key":"482_CR30","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jsat.2006.10.004","volume":"32","author":"H Hagedorn","year":"2007","unstructured":"Hagedorn H, Dieperink E, Dingmann D, et al. Integrating hepatitis prevention services into a substance use disorder clinic. J Subst Abuse Treat. 2007;32(4):391\u20138. https:\/\/doi.org\/10.1016\/j.jsat.2006.10.004.","journal-title":"J Subst Abuse Treat"},{"issue":"8","key":"482_CR31","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s11606-015-3317-3","volume":"30","author":"HJ Hagedorn","year":"2015","unstructured":"Hagedorn HJ, Rettmann N, Dieperink E, Knott A, Landon BE. A training model for implementing hepatitis prevention services in substance use disorder clinics: a qualitative evaluation. J Gen Intern Med. 2015;30(8):1215\u201321. https:\/\/doi.org\/10.1007\/s11606-015-3317-3.","journal-title":"J Gen Intern Med"},{"issue":"Suppl 4","key":"482_CR32","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1007\/s11606-014-3027-2","volume":"29","author":"JE Kirchner","year":"2014","unstructured":"Kirchner JE, Ritchie MJ, Pitcock JA, Parker LE, Curran GM, Fortney JC. Outcomes of a partnered facilitation strategy to implement primary care-mental health. J Gen Intern Med. 2014;29(Suppl 4):904\u201312. https:\/\/doi.org\/10.1007\/s11606-014-3027-2.","journal-title":"J Gen Intern Med"},{"issue":"14","key":"482_CR33","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1007\/s11606-021-07274-7","volume":"37","author":"HJ Hagedorn","year":"2022","unstructured":"Hagedorn HJ, Gustavson AM, Ackland PE, et al. Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): an implementation trial in eight veterans health administration facilities. J Gen Intern Med. 2022;37(14):3594\u2013602. https:\/\/doi.org\/10.1007\/s11606-021-07274-7.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"482_CR34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s43058-021-00119-8","volume":"2","author":"AM Gustavson","year":"2021","unstructured":"Gustavson AM, Wisdom JP, Kenny ME, et al. Early impacts of a multi-faceted implementation strategy to increase use of medication treatments for opioid use disorder in the Veterans Health Administration. Implement Sci Commun. 2021;2(1):20. https:\/\/doi.org\/10.1186\/s43058-021-00119-8.","journal-title":"Implement Sci Commun"},{"issue":"3","key":"482_CR35","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/08897077.2020.1787299","volume":"41","author":"AJ Gordon","year":"2020","unstructured":"Gordon AJ, Drexler K, Hawkins EJ, et al. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities. Subst Abuse. 2020;41(3):275\u201382. https:\/\/doi.org\/10.1080\/08897077.2020.1787299.","journal-title":"Subst Abuse"},{"issue":"1","key":"482_CR36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13722-021-00263-5","volume":"16","author":"EJ Hawkins","year":"2021","unstructured":"Hawkins EJ, Danner AN, Malte CA, et al. Clinical leaders and providers\u2019 perspectives on delivering medications for the treatment of opioid use disorder in Veteran Affairs\u2019 facilities. Addict Sci Clin Pract. 2021;16(1):55. https:\/\/doi.org\/10.1186\/s13722-021-00263-5.","journal-title":"Addict Sci Clin Pract"},{"issue":"12","key":"482_CR37","doi-asserted-by":"publisher","first-page":"e2137238","DOI":"10.1001\/jamanetworkopen.2021.37238","volume":"4","author":"EJ Hawkins","year":"2021","unstructured":"Hawkins EJ, Malte CA, Gordon AJ, et al. Accessibility to medication for opioid use disorder after interventions to improve prescribing among nonaddiction clinics in the US veterans health care system. JAMA Netw Open. 2021;4(12):e2137238. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.37238.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"482_CR38","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1177\/0272989X20960455","volume":"40","author":"TH Wagner","year":"2020","unstructured":"Wagner TH, Yoon J, Jacobs JC, et al. Estimating costs of an implementation intervention. Med Decis Mak Int J Soc Med Decis Mak. 2020;40(8):959\u201367. https:\/\/doi.org\/10.1177\/0272989X20960455.","journal-title":"Med Decis Mak Int J Soc Med Decis Mak"},{"key":"482_CR39","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.childyouth.2013.10.006","volume":"39","author":"L Saldana","year":"2014","unstructured":"Saldana L, Chamberlain P, Bradford WD, Campbell M, Landsverk J. The cost of implementing new strategies (COINS): a method for mapping implementation resources using the stages of implementation completion. Child Youth Serv Rev. 2014;39:177\u201382. https:\/\/doi.org\/10.1016\/j.childyouth.2013.10.006.","journal-title":"Child Youth Serv Rev"},{"issue":"1","key":"482_CR40","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13012-021-01143-x","volume":"16","author":"AB Eisman","year":"2021","unstructured":"Eisman AB, Quanbeck A, Bounthavong M, Panattoni L, Glasgow RE. Implementation science issues in understanding, collecting, and using cost estimates: a multi-stakeholder perspective. Implement Sci. 2021;16(1):75. https:\/\/doi.org\/10.1186\/s13012-021-01143-x.","journal-title":"Implement Sci"},{"issue":"1","key":"482_CR41","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13012-021-01094-3","volume":"16","author":"DM Bowser","year":"2021","unstructured":"Bowser DM, Henry BF, McCollister KE. Cost analysis in implementation studies of evidence-based practices for mental health and substance use disorders: a systematic review. Implement Sci. 2021;16(1):26. https:\/\/doi.org\/10.1186\/s13012-021-01094-3.","journal-title":"Implement Sci"},{"issue":"7 Suppl 1","key":"482_CR42","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1097\/MLR.0b013e31819e1f3f","volume":"47","author":"PG Barnett","year":"2009","unstructured":"Barnett PG. An improved set of standards for finding cost for cost-effectiveness analysis. Med Care. 2009;47(7 Suppl 1):S82-88. https:\/\/doi.org\/10.1097\/MLR.0b013e31819e1f3f.","journal-title":"Med Care"},{"issue":"1","key":"482_CR43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13012-019-0853-y","volume":"14","author":"RC Gale","year":"2019","unstructured":"Gale RC, Wu J, Erhardt T, et al. Comparison of rapid vs in-depth qualitative analytic methods from a process evaluation of academic detailing in the Veterans Health Administration. Implement Sci. 2019;14(1):11. https:\/\/doi.org\/10.1186\/s13012-019-0853-y.","journal-title":"Implement Sci"},{"issue":"3","key":"482_CR44","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s13142-017-0501-5","volume":"7","author":"AB Hamilton","year":"2017","unstructured":"Hamilton AB, Brunner J, Cain C, et al. Engaging multilevel stakeholders in an implementation trial of evidence-based quality improvement in VA women\u2019s health primary care. Transl Behav Med. 2017;7(3):478\u201385. https:\/\/doi.org\/10.1007\/s13142-017-0501-5.","journal-title":"Transl Behav Med"},{"issue":"2","key":"482_CR45","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/ajad.13260","volume":"31","author":"AJ Gordon","year":"2022","unstructured":"Gordon AJ, Kenny M, Dungan M, et al. Are x-waiver trainings enough? Facilitators and barriers to buprenorphine prescribing after x-waiver trainings. Am J Addict. 2022;31(2):152\u20138. https:\/\/doi.org\/10.1111\/ajad.13260.","journal-title":"Am J Addict"},{"key":"482_CR46","unstructured":"American Academy of Addication Psychiatry. American Academy of Addiction Psychiatry - X-Waiver Training. 8 hour and 24 hour X-waiver training. https:\/\/www.aaap.org\/education\/waiver-training\/. Accessed 31 Jan 2022."},{"key":"482_CR47","unstructured":"Providers Clinical Support System. Medication assisted treatment for opioid use disorder overview. Providers Clinical Support System. https:\/\/pcssnow.org\/medications-for-opioid-use-disorder\/. Accessed 7 Feb 2022."},{"key":"482_CR48","unstructured":"Ritchie MJ, Dollar KM, Miller CJ, et al. Using implementation facilitation to improve care in the Veterans Health Administration (version 2). Veterans Health Adm Qual Enhanc Res Initiat QUERI Team-Based Behav Health. 2017. https:\/\/www.queri.research.va.gov\/tools\/implementation.cfm. Accessed 6 Feb 2023."},{"key":"482_CR49","unstructured":"VA Health Economics Resource Center. Cost of VA staff & labor. https:\/\/www.herc.research.va.gov\/include\/page.asp?id=cost-stf-labor. Accessed 3 Aug 2020."},{"key":"482_CR50","volume-title":"Researchers\u2019 guide to estimating VHA labor costs: FY2000 to FY2022. Dataset","author":"PG Barnett","year":"2023","unstructured":"Barnett PG, Dally SK, Scott WJ. Researchers\u2019 guide to estimating VHA labor costs: FY2000 to FY2022. Dataset. Menlo Park: VA Palo Alto, Health Economics Resource Center; 2023."},{"key":"482_CR51","unstructured":"U.S. Department of Veterans Affairs, Office of Research & Development. HSR&D Merit Review Award (Parent I01). 2021. https:\/\/www.va.gov\/files\/2022-07\/hx-22-001-parent.pdf. Accessed 6 Feb 2023."},{"issue":"4","key":"482_CR52","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s11606-019-05537-y","volume":"35","author":"MJ Ritchie","year":"2020","unstructured":"Ritchie MJ, Kirchner JE, Townsend JC, Pitcock JA, Dollar KM, Liu CF. Time and organizational cost for facilitating implementation of primary care mental health integration. J Gen Intern Med. 2020;35(4):1001\u201310. https:\/\/doi.org\/10.1007\/s11606-019-05537-y.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"482_CR53","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2014;17(1):5\u201314. https:\/\/doi.org\/10.1016\/j.jval.2013.08.2291.","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"482_CR54","unstructured":"Substance Abuse and Mental Health Services Administration. Removal of DATA Waiver (X-Waiver) Requirement. 2023. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/removal-data-waiver-requirement. Accessed 6 Feb 2023."},{"issue":"1","key":"482_CR55","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s43058-021-00168-z","volume":"2","author":"CW Hartmann","year":"2021","unstructured":"Hartmann CW, Engle RL, Pimentel CB, et al. Virtual external implementation facilitation: successful methods for remotely engaging groups in quality improvement. Implement Sci Commun. 2021;2(1):66. https:\/\/doi.org\/10.1186\/s43058-021-00168-z.","journal-title":"Implement Sci Commun"},{"issue":"7","key":"482_CR56","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1001\/jamapsychiatry.2021.0247","volume":"78","author":"M Fairley","year":"2021","unstructured":"Fairley M, Humphreys K, Joyce VR, et al. Cost-effectiveness of treatments for opioid use disorder. JAMA Psychiat. 2021;78(7):767\u201377. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.0247.","journal-title":"JAMA Psychiat"},{"key":"482_CR57","doi-asserted-by":"publisher","first-page":"108350","DOI":"10.1016\/j.drugalcdep.2020.108350","volume":"218","author":"C Florence","year":"2021","unstructured":"Florence C, Luo F, Rice K. The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017. Drug Alcohol Depend. 2021;218:108350. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108350.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"482_CR58","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13012-021-01137-9","volume":"16","author":"AR Dopp","year":"2021","unstructured":"Dopp AR, Kerns SEU, Panattoni L, et al. Translating economic evaluations into financing strategies for implementing evidence-based practices. Implement Sci. 2021;16(1):66. https:\/\/doi.org\/10.1186\/s13012-021-01137-9.","journal-title":"Implement Sci"},{"issue":"4 Suppl Va","key":"482_CR59","first-page":"AS9","volume":"37","author":"PG Barnett","year":"1999","unstructured":"Barnett PG. Review of methods to determine VA health care costs. Med Care. 1999;37(4 Suppl Va):AS9-17.","journal-title":"Med Care"},{"issue":"7 Suppl 1","key":"482_CR60","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1097\/MLR.0b013e31819bc064","volume":"47","author":"KD Frick","year":"2009","unstructured":"Frick KD. Micro-costing quantity data collection methods. Med Care. 2009;47(7 Suppl 1):S76\u201381. https:\/\/doi.org\/10.1097\/MLR.0b013e31819bc064.","journal-title":"Med Care"},{"issue":"3","key":"482_CR61","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2165\/00019053-200927030-00001","volume":"27","author":"D Polsky","year":"2009","unstructured":"Polsky D, Glick H. Costing and cost analysis in randomised trials: caveat emptor. Pharmacoeconomics. 2009;27(3):179\u201388.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"482_CR62","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13012-020-00993-1","volume":"15","author":"Z Cidav","year":"2020","unstructured":"Cidav Z, Mandell D, Pyne J, Beidas R, Curran G, Marcus S. A pragmatic method for costing implementation strategies using time-driven activity-based costing. Implement Sci. 2020;15(1):28. https:\/\/doi.org\/10.1186\/s13012-020-00993-1.","journal-title":"Implement Sci"},{"issue":"1","key":"482_CR63","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/1748-5908-8-139","volume":"8","author":"EK Proctor","year":"2013","unstructured":"Proctor EK, Powell BJ, McMillen JC. Implementation strategies: recommendations for specifying and reporting. Implement Sci. 2013;8(1):139. https:\/\/doi.org\/10.1186\/1748-5908-8-139.","journal-title":"Implement Sci"},{"key":"482_CR64","doi-asserted-by":"crossref","unstructured":"Kaplan RS, Anderson SR. Time-driven activity-based costing. Harv Bus Rev. 2004. https:\/\/hbr.org\/2004\/11\/time-driven-activity-based-costing. Accessed 6 Feb 2023.","DOI":"10.2139\/ssrn.485443"},{"key":"482_CR65","unstructured":"U.S. Government Accountability Office. Results of studies on federal pay varied due to differing methodologies. 2012. p. 66. https:\/\/www.gao.gov\/assets\/gao-12-564.pdf. Accessed 7 Mar 2023."},{"issue":"1","key":"482_CR66","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/JHM-D-17-00164","volume":"64","author":"A Mahajan","year":"2019","unstructured":"Mahajan A, Madhani P, Chitikeshi S, Selvaganesan P, Russell A, Mahajan P. Advanced data analytics for improved decision-making at a veterans affairs medical center. J Healthc Manag Am Coll Healthc Exec. 2019;64(1):54\u201362. https:\/\/doi.org\/10.1097\/JHM-D-17-00164.","journal-title":"J Healthc Manag Am Coll Healthc Exec"},{"issue":"1","key":"482_CR67","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12875-018-0783-9","volume":"19","author":"KF Giannitrapani","year":"2018","unstructured":"Giannitrapani KF, Glassman PA, Vang D, et al. Expanding the role of clinical pharmacists on interdisciplinary primary care teams for chronic pain and opioid management. BMC Fam Pract. 2018;19(1):107. https:\/\/doi.org\/10.1186\/s12875-018-0783-9.","journal-title":"BMC Fam Pract"}],"container-title":["Implementation Science Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43058-023-00482-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43058-023-00482-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43058-023-00482-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T14:13:54Z","timestamp":1700403234000},"score":1,"resource":{"primary":{"URL":"https:\/\/implementationsciencecomms.biomedcentral.com\/articles\/10.1186\/s43058-023-00482-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["482"],"URL":"https:\/\/doi.org\/10.1186\/s43058-023-00482-8","relation":{},"ISSN":["2662-2211"],"issn-type":[{"value":"2662-2211","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]},"assertion":[{"value":"13 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by VA Central IRB 16-23.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"91"}}